Exploring the efficacy and safety of laser interstitial thermal therapy for recurrent high-grade glioma: the first prospective cohort in China
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03779-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Yihe Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Neoplasm Recurrence, Local, Laser Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology.
Abstract (Originalsprache)
OBJECTIVE: Recurrent high-grade gliomas are complicated cancers that require additional treatment options. Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is a safe method for treating recurrent high-grade glioma; however, its use in China has not been reported. In this study, we aimed to investigate the safety and efficacy of an MRgLITT system (SinoVision™) developed in China for treating recurrent high-grade glioma. METHODS: We included a prospective cohort of patients with recurrent high-grade glioma treated with the Chinese MRgLITT system between March 2021 and December 2022. Clinical data, including basic information, complication rates, outcomes, and survival analyses, were collected for patients who had at least 12 months of follow-up. RESULTS: 32 patients who completed a rountine follow-up period were enrolled. The estimated 1-year overall survival rate was 65.63%, including 56.52% and 88.89% patients with World Health Organization Grades IV and III gliomas, respectively. Baseline Karnofsky Performance Scale score, tumor grade and volume, and post-LITT chemo- and or radiotherapy were positive factors associated with MRgLITT for recurrent high-grade glioma outcomes. The overall complication rate was 9.38%. CONCLUSION: The Chinese MRgLITT system is a safe and effective treatment option for recurrent high-grade glioma. As it is a minimally invasive treatment approach that can be tailored to the individual's anatomy and physiology, MRg LITT may offer a viable alternative for patients who are not suitable candidates for conventional surgical resection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Clinical Research Center for Epilepsy, Capital Medical University, Beijing, China.
- Department of Radiology, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Department of Nuclear Medicine, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing, 100053, China.
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China. shanyongzhi@xwhosp.org.
- Clinical Research Center for Epilepsy, Capital Medical University, Beijing, China. shanyongzhi@xwhosp.org.
Förderung
- National Natural Science Foundation of China
- Ministry of Science and Technology
Zitieren
APA
Wang, Y., Chen, S., Shi, J., Tang, T., Dai, Y., Xu, J., Wei, P., Fan, X., Lu, J., Shan, Y., & Zhao, G. (2024). Exploring the efficacy and safety of laser interstitial thermal therapy for recurrent high-grade glioma: the first prospective cohort in China. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03779-9
Vancouver
Wang Y, Chen S, Shi J, Tang T, Dai Y, Xu J, et al. Exploring the efficacy and safety of laser interstitial thermal therapy for recurrent high-grade glioma: the first prospective cohort in China. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03779-9
BibTeX
@article{Wang2024,
author = {Wang, Yihe and Chen, Sichang and Shi, Jianwei and Tang, Ting and Dai, Yang and Xu, Jinkun and Wei, Penghu and Fan, Xiaotong and Lu, Jie and Shan, Yongzhi and Zhao, Guoguang},
title = {Exploring the efficacy and safety of laser interstitial thermal therapy for recurrent high-grade glioma: the first prospective cohort in China},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03779-9}
}
EUVIMED